Natco Pharma settles patent litigation over generic version of anti-cancer drug Kyprolis

New Delhi: Natco Pharma recently said it has settled patent litigation with Onyx Therapeutics Inc in the US over a generic version of Kyprolis, an anti-cancer drug. The company said it has reached a settlement agreement with Onyx Therapeutics Inc related to generic versions of 10mg, 30mg and 60mg of Kyprolis, Natco Pharma said in a regulatory filing.

Natco has tied up with Breckenridge Pharmaceutical Inc to market the product in the US.

"The parties have reached a settlement agreement and the district court case has been dismissed. By virtue of the settlement, Natco and Breckenridge have been granted a licence permitting the launch of their generic carfilzomib product on a date that is held as confidential in 2027 or sooner depending on certain occurrences," the company added.

The company believes its 10mg ANDA is sole first to file and could be eligible for 180-day marketing exclusivity for the 10mg strength under certain circumstances, Natco said.

Sales of Kyprolis stood at around USD 586 million for the year ended December 2018 in the US.

Kyprolis is the trade name for the generic drug Carfilzomib. In some cases, health care professionals may use the generic name Carfilzomib when referring to the trade name Kyprolis. Kyprolis is a targeted therapy and is classified as a Proteasome Inhibitor.

Based in Hyderabad, Natco Pharma was established in 1981 as a private limited company. The company develops, manufactures and markets finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company's major product categories include Domestic Formulations, International Formulations, APIs and Blockbusters.